Opinion|Videos|March 26, 2025
Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
Author(s)Caron A. Jacobson, MD, MMSc, Peter Riedell, MD
Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.
Advertisement
Video content above is prompted by the following:
- At ASH last year, there was an oral presentation looking at real-world outcomes of liso-cel as second-line therapy for R/R LBCL from the CIMBTR registry. What were some data highlights, and how do real-world outcomes influence your day-to-day decision-making?
- What patient factors and/or disease characteristics do you consider when selecting between axi-cel vs liso-cel in the second-line setting? There was updated following from a MAIC of liso-cel vs axi-cel in the second line for R/R LBCL from ASH 2024. Has this data influenced your CAR T selection?
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
Revisit Every OncLive On Air Episode From June 2026
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5